九芝堂 (000989)

JIUZHITANG CO.,LTD

ASZ

Tags

ImmunotherapyInnovative DrugsMedical Aesthetics ConceptPharmaceutical ManufacturingControl ChangeDelisting Warning RemovalHigh-Dividend Stocks

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 85594.20
  • Circulating A-Shares(W): 69415.38
  • Earnings Per Share(RMB): 0.1791
  • Net Assets Per Share(RMB): 4.2651
  • Operating Revenue(W RMB): 162745.33
  • Total Profit(W RMB): 20936.88
  • Net Profit Attributable to Parent(W RMB): 15153.16
  • Net Profit Growth Rate(%): -36.94
  • Weighted Return on Equity(%): 4.1100
  • Operating Cash Flow Per Share(RMB): 0.3630
  • Undistributed Profit Per Share(RMB): 1.0217
  • Capital Reserve Per Share(RMB): 1.8091

2. Main Business

The main business covers:

  • Research, development, production and sales of traditional Chinese medicine

3. Company Basic Information

  • Company Name: Jiuzhitang Co., Ltd.
  • Listing Date: 2000-06-28
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 339 Tongzipo West Road, Changsha City, Hunan Province
  • Website: www.hnjzt.com
  • Company Profile: The company was established in May 1999 as a joint-stock company by five promoters including Changsha Jiuzhitang (Group) Co., Ltd., SDIC Pharmaceutical Investment Co., Ltd., Hainan Xiangyuan Economic and Trade Company, Hunan Pharmaceutical Company, and Hunan Changsha Friendship (Group) Co., Ltd. Among them, Changsha Jiuzhitang (Group) Co., Ltd. contributed net assets and equity, converted into 78.12 million state shares; the other four promoters contributed cash, totaling 10.5 million legal person shares. As of December 31, 1999, the company's total share capital was 88.62 million shares. After the public issuance of 40 million RMB ordinary shares on June 9 and 10, 2000, the company's total share capital reached 128.62 million shares.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Heilongjiang Cheneng Gongda Venture Capital Co., Ltd. General Legal Person 20573.06 29.64
2 ICBC Credit Suisse Frontier Medical Equity Securities Investment Fund A Fund 400.00 0.58
3 Hong Kong Securities Clearing Company Ltd. Northbound Funds 235.73 0.34
4 ICBC Credit Suisse Pharmaceutical Health Industry Equity Securities Investment Fund A Fund 186.93 0.27
5 Yimin Innovation Advantage Hybrid Securities Investment Fund Fund 51.54 0.07

5. Concept Sectors

  • Immunotherapy
  • Medical Aesthetics Concept
  • Innovative Drugs
  • Delisting Risk Removed
  • High Dividend Stocks
  • Control Change

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information